Anti-Coagulant + Anti-Platelet Therapy for Stroke Prevention
(CAPTIVA Trial)
Trial Summary
What is the purpose of this trial?
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
Do I need to stop my current medications to join the trial?
The trial does not specify if you need to stop your current medications, but it does mention that you cannot take any antithrombotic medication other than aspirin, unless it's for specific conditions like DVT prevention. It's best to discuss your current medications with the trial team.
What data supports the effectiveness of the drug Ticagrelor (Brilinta) for stroke prevention?
Is the combination of anti-coagulant and anti-platelet therapy generally safe for humans?
How is the drug combination of Clopidogrel, Rivaroxaban, and Ticagrelor unique for stroke prevention?
This drug combination is unique because it combines both antiplatelet and anticoagulant therapies, which can significantly reduce the risk of recurrent strokes compared to using aspirin alone, although it may increase the risk of bleeding. This approach targets multiple pathways involved in blood clot formation, offering a more comprehensive prevention strategy for patients with atherosclerotic diseases.89101112
Research Team
Brian L. Hoh, MD, MBA
Principal Investigator
University of Florida
Marc I. Chimowitz, MBChB
Principal Investigator
Medical University of South Carolina
Eligibility Criteria
Adults aged 30-80 with recent symptoms or signs of a stroke due to 70-99% blockage in a major brain artery, who can swallow pills and have certain heart or blood vessel conditions. Excluded are those with previous stent treatments for the lesion, bleeding disorders, severe liver issues, uncontrolled high blood pressure, substance abuse, certain heart conditions that could cause clots, planned major surgeries within 90 days after joining the trial, severe neurological deficits preventing independence, life expectancy under one year due to other illnesses.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either ticagrelor, rivaroxaban, or clopidogrel in combination with aspirin to prevent stroke and vascular death
Follow-up
Participants are monitored for safety and effectiveness after treatment, focusing on ischemic stroke, intracerebral hemorrhage, or vascular death
Treatment Details
Interventions
- Clopidogrel
- Rivaroxaban
- Ticagrelor
Clopidogrel is already approved in European Union, United States, Canada, Japan, China for the following indications:
- Prevention of atherothrombotic events in patients with myocardial infarction, stroke, or peripheral arterial disease
- Acute coronary syndrome
- Reduction of myocardial infarction and stroke in patients with acute coronary syndrome
- Reduction of myocardial infarction and stroke in patients with recent myocardial infarction, recent stroke, or established peripheral arterial disease
- Prevention of atherothrombotic events in patients with myocardial infarction, stroke, or peripheral arterial disease
- Acute coronary syndrome
- Prevention of recurrence of ischemic cerebrovascular disorder
- Prevention of recurrence of myocardial infarction
- Prevention of atherothrombotic events in patients with myocardial infarction, stroke, or peripheral arterial disease
- Acute coronary syndrome
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Florida
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator
University of Cincinnati
Collaborator
Medical University of South Carolina
Collaborator
Janssen Scientific Affairs, LLC
Industry Sponsor
Ricardo Attar
Janssen Scientific Affairs, LLC
Chief Executive Officer since 2008
PhD in Molecular Biology, University of Buenos Aires
Dr. Anastasia G. Daifotis
Janssen Scientific Affairs, LLC
Chief Medical Officer since 2023
MD
AstraZeneca
Industry Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology